Video

Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

Author(s):

Kim N. Chi, MD, BC Cancer

Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Related Content
Philip Sutera, MD, of Johns Hopkins University School of Medicine
May 30th 2024

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
May 6th 2024

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Marcelo Bigarella, MD
May 4th 2024

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer